Drugs / TRS005
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05395533 | Sep 2020 → Jul 2025 overdue | B-cell non-Hodgkin lymphoma | Zhejiang Teruisi Pharmaceutical Inc. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07035379 | Sep 2025 → Sep 2026 expected | diffuse large B-cell lymphoma | Zhejiang Teruisi Pharmaceutical Inc. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06886139 | Sep 2025 → Jan 2027 expected | diffuse large B-cell lymphoma | Zhejiang Teruisi Pharmaceutical Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRS005 | “Recombinant CD20 monoclonal antibody-MMAE conjugte for injection (TRS005)” NCT05395533 ↗ |
| Modality | Monoclonal antibody | “CD20 monoclonal antibody” NCT05395533 ↗ |
| Route | Intravenous | “by intravenous drip” NCT05395533 ↗ |